UPB · Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Market Cap
150.1M
52 Wk Range
$2.69 - $33.68
Previous Close
$2.99
Open
$2.95
Volume
1,051,217
Day Range
$2.70 - $2.96
Enterprise Value
-110.8M
Cash
261.3M
Avg Qtr Burn
-35.62M
Insider Ownership
14.78%
Institutional Own.
92.36%
Qtr Updated
Jun 30th 2026
